Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital Midtown
mi
from
Atlanta, GA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital-Winship Cancer Institute
mi
from
Atlanta, GA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital-Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Siteman Cancer Center at West County Hospital
mi
from
Creve Coeur, MO
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Siteman Cancer Center at West County Hospital
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Keck Medical Center of USC Pasadena
mi
from
Pasadena, CA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Keck Medical Center of USC Pasadena
mi
from
Pasadena, CA
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Siteman Cancer Center at Saint Peters Hospital
mi
from
Saint Peters, MO
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Siteman Cancer Center at Saint Peters Hospital
mi
from
Saint Peters, MO
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Siteman Cancer Center at Christian Hospital
mi
from
Saint Louis, MO
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Siteman Cancer Center at Christian Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
A Phase I Study of Lenalidomide Plus Pembrolizumab in Patients With Relapsed and/or Refractory Solid Tumors With Phase II Expansion in Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
A Phase I Study of Lenalidomide Plus Pembrolizumab in Patients With Relapsed and/or Refractory Solid Tumors With Phase II Expansion in Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated:  12/31/1969
Southwestern Regional Medical Center
mi
from
Tulsa, OK
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated: 12/31/1969
Southwestern Regional Medical Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin-Madison
mi
from
Madison, WI
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated:  12/31/1969
Toronto General Hospital
mi
from
Toronto,
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated: 12/31/1969
Toronto General Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated:  12/31/1969
Southeastern Regional Medical Center
mi
from
Atlanta, GA
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated: 12/31/1969
Southeastern Regional Medical Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated:  12/31/1969
Providence Medical Research Center
mi
from
Spokane, WA
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated: 12/31/1969
Providence Medical Research Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Hospital Network
mi
from
Elk Grove Village, IL
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Hospital Network
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Autologous Stem Cell Treatment for Chronic Lung Disease Study
Autologous Stem Cell Treatment for Chronic Lung Disease Study
Status: Enrolling
Updated:  12/31/1969
Lung Institute Dallas
mi
from
Dallas, TX
Autologous Stem Cell Treatment for Chronic Lung Disease Study
Autologous Stem Cell Treatment for Chronic Lung Disease Study
Status: Enrolling
Updated: 12/31/1969
Lung Institute Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Center
mi
from
Boston, MA
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
City of Hope
mi
from
Duarte, CA
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Assessment of Lung Movement With Computed Tomography (CT)
Assessment of Lung Movement With CT in Healthy Subjects and Patients With ILD
Status: Enrolling
Updated:  12/31/1969
University Of Missouri-Columbia
mi
from
Columbia, MO
Assessment of Lung Movement With Computed Tomography (CT)
Assessment of Lung Movement With CT in Healthy Subjects and Patients With ILD
Status: Enrolling
Updated: 12/31/1969
University Of Missouri-Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
University of California San Diego Medical Center, Moores Cancer Center
mi
from
La Jolla, CA
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
University of California San Diego Medical Center, Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
Carolina Bio-Oncology Institute, PLLC
mi
from
Huntersville, NC
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
Carolina Bio-Oncology Institute, PLLC
mi
from
Huntersville, NC
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Health System
mi
from
Philadelphia, PA
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials